A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for in vivo studies
Andrea Chicca, Daniel Bátora, Christoph Ullmer, Antonello Caruso, Sabine Grüner, Jürgen Fingerle, Thomas Härtung, Roland Degen, Matthias Müller, Uwe Grether, Pál Pacher, Jürg Gertsch
This paper develops and characterizes RNB-61, a potent and selective CB2R agonist with favorable pharmacokinetics, showing nephroprotective effects in kidney injury models.
ACS Pharmacology & Translational Science · Jul 9, 2024Peer-reviewedPharmacology & Toxicology